BRIEF published on 06/16/2026 at 21:21, 4 months 24 days ago Medincell : Résultats et initiatives clés pour 2025-2026 Innovation R&D Trésorerie Royalties Medincell
PRESS RELEASE published on 06/16/2026 at 21:16, 4 months 24 days ago Informations privilégiées / Communiqué sur comptes, résultats Medincell publie ses résultats financiers annuels consolidés pour l'exercice 2025-2026, mettant en avant la solidité opérationnelle et la transition vers un modèle reposant sur l'innovation et les revenus récurrents Résultats Financiers Innovation Revenus Récurrents Medincell Exercice 2025-2026
BRIEF published on 05/21/2026 at 19:29, 5 months 21 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
BRIEF published on 05/21/2026 at 19:29, 5 months 21 days ago L'EMA accepte la demande de Teva pour un traitement de la schizophrénie à action prolongée Traitement De La Schizophrénie Teva Pharmaceuticals Approbation De L'EMA Olanzapine Injectable Formule À Action Prolongée
PRESS RELEASE published on 05/21/2026 at 19:24, 5 months 21 days ago Informations privilégiées / Autres communiqués L'EMA accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie. Technologie de libération prolongée SteadyTeq(TM) utilisée Schizophrénie Teva EMA Olanzapine LAI SteadyTeq
PRESS RELEASE published on 05/21/2026 at 19:24, 5 months 21 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 6 months 12 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 6 months 12 days ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
BRIEF published on 04/29/2026 at 13:44, 6 months 12 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 6 months 12 days ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
Published on 11/11/2026 at 19:31, 1 hour 23 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 4 hours 24 minutes ago ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 6 hours 29 minutes ago Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 6 hours 54 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 6 hours 54 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 19:29, 1 hour 25 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 2 hours 12 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 2 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 3 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 3 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 3 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
